2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Cell Expansion, Treatment Considerations, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Pharmacology, Biological Processes, Immune Mechanism, Diseases, Bleeding and Clotting, Platelet Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, T Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Animal Model
PAPER

2378 Local, antigen-triggered delivery of T-cell engagers to AML by CD70-sensing synthetic receptor T cells

Corynn Kasap, MD, PhD, Khadija Kone, N/A2, Ananya Manoj3, Daniel Waller, PhD4, McKenna Crawford5, Bonell Patino-Escobar, MD6, Sruthi Raguveer7, Khadija Yousuf8, Max Foisey9, Jose M. Rivera10, Hua Li, PhD11, Juan Antonio Camara-Serrano, PhD12, Paul Phojanakong, BA13, Yan Zeng, MD14, Veronica Steri, PhD15, Kole Roybal, PhD16, Elliot Stieglitz, MD17, Arun Wiita, MD, PhD18
1 Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, United States, Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, United States
2 Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, United States
3 Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, United States
4 Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, United States
5 Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, United States
6 Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, United States
7 Chemistry and Chemical Biology, University of California, San Francisco,, San Francisco, California, United States
8 Department of Pediatrics, University of California San Francisco Benioff Children’s Hospitals, San Francisco, California, United States
9 Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, United States, Parker Institute for Cancer Immunotherapy, San Francisco, California, United States
10 Department of Pediatrics, University of California San Francisco Benioff Children’s Hospitals, San Francisco, California, United States
11 Preclinical Therapeutics Core. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco,, San Francisco, California, United States
12 Preclinical Therapeutics Core. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco,, San Francisco, California, United States
13 Preclinical Therapeutics Core. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco,, San Francisco, California, United States
14 Preclinical Therapeutics Core. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco,, San Francisco, California, United States
15 Preclinical Therapeutics Core. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco,, San Francisco, California, United States
16 Chan Zuckerberg Biohub, San Francisco, California, United States, Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, United States, Gladstone-UCSF Institute of Genomic Immunology, San Francisco, California, United States, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, United States, Parker Institute for Cancer Immunotherapy, San Francisco, California, United States, UCSF Cell Design Institute, San Francisco, California, United States
17 Department of Pediatrics, University of California San Francisco Benioff Children’s Hospitals, San Francisco, California, United States
18 Chan Zuckerberg Biohub, San Francisco, California, United States, Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, United States, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, United States

For adult patients with relapsed/refractory acute myeloid leukemia (AML), median survival remains less than 1 year. Stem cell transplant is often the only curative option; for those unable to undergo transplant, therapeutic options remain severely limited. Though Chimeric Antigen Receptor T-cell (CAR-T) and bispecific T-cell engager (TCE) antibody therapies have improved survival in B-cell malignancies, extending these strategies to AML has been stymied by lack of tumor-specific antigens, resulting in intolerable on-target, off-tumor toxicities. CD70 is an attractive CAR-T target, with high expression on AML and absent expression on normal hematopoietic stem and progenitor cells. However, AML's intratumoral immunophenotypic heterogeneity raises the risk of antigen-negative relapse with single-target CAR-T.

We reasoned the synthetic intramembrane proteolysis receptor (SNIPR) platform (Zhu et al., Cell 2022) could surmount both obstacles. Unlike the CAR framework, which triggers an intrinsic T cell activation program upon antigen sensing, SNIPRs convert antigen binding to a defined transcriptional output, here secretion of TCEs targeting CD33, CD123, and CLL1. Paired with multiple TCE payloads, anti-CD70 SNIPR-T cells could secrete therapeutic TCEs only in proximity of residual AML, preventing single-antigen negative escape while avoiding the toxicity of systemically delivered TCEs.

To assess optimal designs, we engineered 30 anti-CD70 SNIPRs (10 binders across 3 receptor frameworks) and tuned performance using varied juxtamembrane and transcriptional activator domains. SNIPRs were lentivirally transduced into primary human CD3+ T cells and assessed for surface expression, basal leak, and dynamic range by induction of a blue fluorescent protein (BFP) response element ± CD70+ targets. Optimized SNIPRs demonstrated >40-fold signal-to-noise BFP expression versus no-antigen control; inclusion of a RAM extension to the framework significantly reduced antigen-independent leak.

We next engineered TCE payloads targeting the abundant AML antigens CD33, CD123, and CLL1, with varied anti-CD3 binding arms. To evaluate complete circuits, TCE response elements were paired to best performing SNIPRs and transduced into primary T cells. SNIPR-TCE T cells were assessed in vitro against CD70+ AML cell lines NOMO-1 and THP-1, with isogenic antigen knock out controls. As TCEs may act at picomolar concentrations, we sought tight antigen-dependent control; TCE secretion was quantified using N-terminal HiBiT tag detection. Secreted TCE payloads were rapid onset and highly trigger-dependent: levels rose >40-fold in 24 hours in the presence versus absence of CD70+ targets, and mediated antigen-specific killing of NOMO-1 and THP-1 (>90% lysis at 1:1 E:T). Cytotoxicity against antigen-negative isogenic lines was comparable to untransduced T cells, demonstrating stringent circuit control.

To demonstrate in vivo anti-leukemic efficacy, we deployed optimized SNIPR-T cells in murine xenograft models of AML. NSG mice bearing luciferase+ NOMO-1 (5 groups, n=5) received 3x10^6 SNIPR T cells lacking a TCE response element, one of three anti-CD70 SNIPR→TCE constructs differing in CD70-binding domain, or anti-CD70 4-1BB CAR T cells. Peripheral blood was monitored twice monthly for SNIPR-T expansion and TCE by HiBiT detection; efficacy was monitored by bioluminescent imaging (BLI). SNIPR T cells were detectable in blood by day 9, demonstrating comparable or superior engraftment to CAR-T despite lacking a CD3zeta domain. SNIPR-triggered TCE was detectable in peripheral blood and declined with tumor burden, consistent with circuit-controlled secretion. Importantly, all SNIPR→TCE constructs cleared NOMO-1 xenografts by BLI comparable to anti-CD70 CAR T cells, while control SNIPR T cells lacking the TCE cassette did not control tumor.

In summary, we describe CD70-sensing SNIPR T cells that achieve leukemia clearance equivalent to anti-CD70 CAR T cells while producing their therapeutic payload only upon antigen engagement, offering potent, local payload delivery. Because the response element is modular and each of three AML-directed engagers functions interchangeably in the same circuit, this architecture is well suited to multiplexed payloads; a dual-TCE cassette and its evaluation in an AML PDX MRD model are ongoing. These data position CD70-SNIPR TCE-delivery as a strategy to eradicate residual, heterogeneous AML while reducing toxicity.

Corynn Kasap, MD, PhD: No relevant conflicts of interest to declare.